Medline Reports Q3 Sales Growth and Raises 2026 Organic Sales Guidance
Medline reported third-quarter net sales of $7.856 billion, up 10.4% year over year, and net income of $318 million, down 1.2%. Adjusted diluted EPS was $0.44, exceeding analyst expectations. It raised its 2026 organic sales growth guidance to 10.0%–10.5%, reaffirmed adjusted EBITDA guidance of $3.3 billion–$3.4 billion, authorized up to $1 billion in share repurchases and prepaid $750 million of principal on its 2033 refinancing term loan.
Medline Inc. announced its financial results for the third quarter ended September 26, 2026, reporting net sales of $7.856 billion, a 10.4% increase compared to the same period in 2025. Net income for the quarter was $318 million, down 1.2% from the prior year, while adjusted diluted EPS reached $0.44, exceeding analyst expectations. The company raised its full-year 2026 organic sales growth guidance to a range of 10.0% to 10.5% and reaffirmed its adjusted EBITDA outlook of $3.3 billion to $3.4 billion.
Additionally, the board of directors authorized a new share repurchase program of up to $1 billion, and the company prepaid $750 million of principal on its 2033 refinancing term loan facility. Management attributed the growth to existing customer expansion and the implementation of new customer signings secured in 2025.